{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:08Z","timestamp":1787786168064,"version":"build-2784847793"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1037,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1111\/j.1365-2133.2012.11142.x","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T11:19:26Z","timestamp":1342264766000},"page":"1145-1152","source":"Crossref","is-referenced-by-count":85,"title":["The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection"],"prefix":"10.1093","volume":"167","author":[{"given":"T.-F.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Szapary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wasfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Ustekinumab Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB1|cit1","unstructured":"World Health Organization Global Tuberculosis Control 2011 http:\/\/www.who.int\/tb\/publications\/global_report\/en\/index.html"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB2|cit2","unstructured":"World Health Organization Media Centre, Tuberculosis Fact Sheet No 104 (March 2012) http:\/\/www.who.int\/mediacentre\/factsheets\/fs104\/en\/index.html"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0140-6736(10)60359-5","article-title":"Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice","volume":"375","author":"Wallis","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB4|cit4","unstructured":"World Health Organization Regional Office for South East Asia Communicable Diseases Department. Tuberculosis. TB\/HIV http:\/\/www.searo.who.int\/en\/section10\/section2097\/section2129.htm"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000237126","article-title":"Interleukin-12","volume":"108","author":"Germann","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14728222.2010.497143","article-title":"Targeting IL-23 in human diseases","volume":"14","author":"D\u2019Elios","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)00605-6","article-title":"Emergence of the Th17 pathway and its role in host defense","volume":"99","author":"O\u2019Quinn","year":"2008","journal-title":"Adv Immunol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.smim.2006.07.010","article-title":"Inborn errors of IL-12\/23- and IFN-\u03b3-mediated immunity: molecular, cellular, and clinical features","volume":"18","author":"Filipe-Santos","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"on behalf of the PEARL Investigators. Efficacy and safety of ustekinumb for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"the Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB16|cit16","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB18|cit18","unstructured":"PDR Network, LLC Isoniazid http:\/\/www.pdr.net\/drugpages\/concisemonograph.aspx?concise=1708"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB19|cit19","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation (2009) http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB20|cit20","article-title":"A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial","author":"Tsai","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB54|cit21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2008.05.033","article-title":"Tuberculosis in the age of biologic therapy","volume":"59","author":"Hernandez","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: new drugs illuminate an old topic","volume":"44","author":"Keane","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"BIOBADASER GROUP Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2008.08891.x","article-title":"Tuberculosis and tumour necrosis factor-\u03b1 inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians","volume":"160","author":"Perlmutter","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","article-title":"Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients","volume":"25","author":"S\u00e1nchez-Moya","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB30|cit30","first-page":"553","article-title":"Clinical experience of QuantiFERON\u00ae-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan","volume":"164","author":"Chiu","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-010-1571-6","article-title":"High incidence of intolerance to tuberculosis chemoprophylaxis","volume":"32","author":"Haroon","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2009.10.012","article-title":"Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment","volume":"77","author":"Bray","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1111\/j.1365-2133.2012.11142.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2012.11142.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2012.11142.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:56:42Z","timestamp":1676365002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/5\/1145\/6614169"}},"subtitle":["Safety of ustekinumab in psoriasis patients with latent tuberculosis"],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11142.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717953009.793459158","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717953009.793459525","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717953009.793459646","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717953009.793458558","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,29]]}}}